Physician profile
Devina Budhu
NPI 1194594341
$1,781.86
in general payments reported to CMS, 2019-2025
18 companies · $786 in 2025
The $786 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $996 · 2025: $786.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,782.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,781.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $338.63 | 2024-2025 | |
| Emd Serono, INC. | $333.35 | 2024-2025 | Mavenclad |
| Lundbeck LLC | $177.12 | 2024-2025 | Rexulti |
| Ucb, INC. | $158.61 | 2024 | Nayzilam |
| Vanda Pharmaceuticals INC. | $130.59 | 2024-2025 | Ponvory |
| Pfizer INC. | $112.56 | 2024-2025 | |
| Axsome Therapeutics, INC. | $95.38 | 2025 | Symbravo |
| Sk Life Science, INC. | $92.02 | 2024 | |
| Eisai INC. | $67.43 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $50.13 | 2024-2025 | Rexulti |
| Amgen INC. | $47.41 | 2024-2025 | Uplizna |
| Cala Health, INC. | $40.62 | 2024 | Cala Kiq, Cala Trio |
| E.R. Squibb & Sons, L.L.C. | $39.73 | 2024 | Zeposia |
| Averitas Pharma INC. | $26.84 | 2025 | Qutenza |
| Lilly USA, LLC | $23.58 | 2024 | Emgality |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tg Therapeutics, INC. | $23.50 | 2025 | |
| Genentech USA, INC. | $16.42 | 2025 | Ocrevus Zunovo |
| Aucta Pharmaceuticals, INC. | $7.94 | 2025 | Motpoly Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devina Budhu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.